William Tai-Wei Ho - 27 Apr 2025 Form 4 Insider Report for IN8BIO, INC. (INAB)

Reporting relationship: PRESIDENT AND CEO, Director, 10%+ Owner
Issuer ticker: INAB
Reported as of: 27 Apr 2025
Net transaction value: +$15,107
SEC form: 4
Accepted by SEC: 07 May 2025, 20:45:13 UTC
Prior SEC filing: 07 Feb 2025
Next SEC filing: 23 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Jason Minio, Attorney-in-Fact

Filing notes and source

Key filing fact

William Tai-Wei Ho filed Form 4 for IN8BIO, INC. (INAB) on 07 May 2025.

Key facts

This page summarizes William Tai-Wei Ho's Form 4 filing for IN8BIO, INC. (INAB).
4 reported transactions and 4 derivative rows are listed below.
Accepted by SEC: 07 May 2025, 20:45.

Change

Previous filing in this sequence was filed on 07 Feb 2025.
Current net transaction value: +$15,107.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001830914 Primary reporting owner

Ho William Tai-Wei

Relationship: PRESIDENT AND CEO, Director, 10%+ Owner
Address: C/O IN8BIO, INC., 350 5TH AVE. SUITE 5330, NEW YORK
Signature: /s/ Jason Minio, Attorney-in-Fact
Signature date: 07 May 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

INAB transaction Derivative

Series B Warrants (right to buy)

Disposed to Issuer

Transaction value
Shares: -81,967
Change %: -100%
Price
Shares after: 0
Date: 27 Apr 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 81,967
Exercise price: $1.50
Footnotes: F1, F2, F3

INAB transaction Derivative

Series B Warrants (right to buy)

Award

Transaction value
Shares: +81,967
Change %
Price
Shares after: 81,967
Date: 27 Apr 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 81,967
Exercise price: $0.4500
Footnotes: F1, F2

INAB transaction Derivative

Series A Warrants (right to buy)

Disposed to Issuer

Transaction value
Shares: -81,967
Change %: -100%
Price
Shares after: 0
Date: 01 May 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 81,967
Exercise price: $0.4500
Footnotes: F2, F4, F5

INAB transaction Derivative

Pre-Funded Warrant (right to buy)

Award

Transaction value: $15,107
Shares: +81,967
Change %
Price: $0.1843
Shares after: 81,967
Date: 01 May 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 81,967
Exercise price: $0.000100
Footnotes: F2, F4, F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share. The exercise price was reduced to $0.45 per share.

Footnote F2

Fully vested and exercisable.

Footnote F3

The reported securities are included within 81,967 units purchased by the Reporting Person on December 13, 2023 for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 81,967 shares of common stock.

Footnote F4

Pursuant to an Exchange Letter Agreement, dated April 26, 2025 (the "Exchange Agreement"), by and between the Company and the Reporting Person, the Reporting Person surrendered to the Company for cancellation the Series A Warrants for a like number of Pre-Funded Warrants to purchase common stock, with a per share exercise price of $0.0001 per share.

Footnote F5

The reported securities are included within 81,967 units purchased by the Reporting Person on December 13, 2023 for $1.22 per unit. Each unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 81,967 shares of common stock.

Footnote F6

The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. The Pre-Funded Warrants are subject to certain exercise limitations.